Cassava Sciences (SAVA) Competitors $2.31 +0.06 (+2.67%) Closing price 04:00 PM EasternExtended Trading$2.31 0.00 (-0.22%) As of 06:01 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock SAVA vs. CRVS, KMDA, AURA, IMAB, YMAB, AQST, VIGL, OLMA, RCKT, and ZYBTShould you be buying Cassava Sciences stock or one of its competitors? The main competitors of Cassava Sciences include Corvus Pharmaceuticals (CRVS), Kamada (KMDA), Aura Biosciences (AURA), I-Mab (IMAB), Y-mAbs Therapeutics (YMAB), Aquestive Therapeutics (AQST), Vigil Neuroscience (VIGL), Olema Pharmaceuticals (OLMA), Rocket Pharmaceuticals (RCKT), and Zhengye Biotechnology (ZYBT). These companies are all part of the "pharmaceutical products" industry. Cassava Sciences vs. Its Competitors Corvus Pharmaceuticals Kamada Aura Biosciences I-Mab Y-mAbs Therapeutics Aquestive Therapeutics Vigil Neuroscience Olema Pharmaceuticals Rocket Pharmaceuticals Zhengye Biotechnology Corvus Pharmaceuticals (NASDAQ:CRVS) and Cassava Sciences (NASDAQ:SAVA) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their dividends, analyst recommendations, earnings, media sentiment, profitability, valuation, risk and institutional ownership. Do insiders and institutionals have more ownership in CRVS or SAVA? 46.6% of Corvus Pharmaceuticals shares are owned by institutional investors. Comparatively, 38.1% of Cassava Sciences shares are owned by institutional investors. 31.3% of Corvus Pharmaceuticals shares are owned by company insiders. Comparatively, 12.2% of Cassava Sciences shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term. Which has more risk and volatility, CRVS or SAVA? Corvus Pharmaceuticals has a beta of 0.42, meaning that its stock price is 58% less volatile than the S&P 500. Comparatively, Cassava Sciences has a beta of -2.05, meaning that its stock price is 305% less volatile than the S&P 500. Does the media prefer CRVS or SAVA? In the previous week, Corvus Pharmaceuticals had 1 more articles in the media than Cassava Sciences. MarketBeat recorded 2 mentions for Corvus Pharmaceuticals and 1 mentions for Cassava Sciences. Corvus Pharmaceuticals' average media sentiment score of 1.62 beat Cassava Sciences' score of 0.94 indicating that Corvus Pharmaceuticals is being referred to more favorably in the media. Company Overall Sentiment Corvus Pharmaceuticals Very Positive Cassava Sciences Positive Is CRVS or SAVA more profitable? Corvus Pharmaceuticals' return on equity of -28.61% beat Cassava Sciences' return on equity.Company Net Margins Return on Equity Return on Assets Corvus PharmaceuticalsN/A -28.61% -18.05% Cassava Sciences N/A -66.16%-53.11% Which has better valuation and earnings, CRVS or SAVA? Corvus Pharmaceuticals is trading at a lower price-to-earnings ratio than Cassava Sciences, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioCorvus PharmaceuticalsN/AN/A-$62.29M-$1.01-5.45Cassava SciencesN/AN/A-$24.34M-$2.55-0.91 Do analysts prefer CRVS or SAVA? Corvus Pharmaceuticals currently has a consensus target price of $15.00, indicating a potential upside of 172.73%. Cassava Sciences has a consensus target price of $2.00, indicating a potential downside of 13.42%. Given Corvus Pharmaceuticals' stronger consensus rating and higher probable upside, equities research analysts clearly believe Corvus Pharmaceuticals is more favorable than Cassava Sciences.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Corvus Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 3.00Cassava Sciences 0 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 2.00 SummaryCorvus Pharmaceuticals beats Cassava Sciences on 11 of the 13 factors compared between the two stocks. Get Cassava Sciences News Delivered to You Automatically Sign up to receive the latest news and ratings for SAVA and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding SAVA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart SAVA vs. The Competition Export to ExcelMetricCassava SciencesMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$111.60M$2.48B$5.74B$9.78BDividend YieldN/A1.67%4.40%4.04%P/E Ratio-0.9122.5330.8326.39Price / SalesN/A506.55382.9086.63Price / CashN/A178.3537.7259.11Price / Book1.276.2910.106.62Net Income-$24.34M$32.94M$3.26B$265.42M7 Day Performance7.94%2.27%3.90%3.58%1 Month Performance-1.70%1.06%3.73%0.46%1 Year Performance-91.98%5.65%37.68%19.41% Cassava Sciences Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)SAVACassava Sciences1.9553 of 5 stars$2.31+2.7%$2.00-13.4%-92.4%$111.60MN/A-0.9130CRVSCorvus Pharmaceuticals3.2223 of 5 stars$5.45-1.8%$15.00+175.2%+34.1%$406.10MN/A-5.4030KMDAKamada4.7569 of 5 stars$7.05-1.8%$13.00+84.4%+23.3%$405.45M$160.95M20.74360Positive NewsAURAAura Biosciences2.0266 of 5 stars$6.52-0.5%$22.00+237.4%-16.1%$405.02MN/A-3.3350IMABI-Mab3.1162 of 5 stars$4.82-5.3%$6.50+34.9%+298.5%$393.60M$3.89M0.00380Earnings ReportAnalyst RevisionGap DownHigh Trading VolumeYMABY-mAbs Therapeutics2.4583 of 5 stars$8.52-0.1%$9.62+12.9%-43.6%$387.13M$85.39M-17.04150AQSTAquestive Therapeutics2.2332 of 5 stars$3.86-3.0%$10.14+162.8%-12.4%$384.94M$44.13M-5.51160Positive NewsVIGLVigil Neuroscience1.7767 of 5 stars$8.05flat$10.80+34.2%N/A$383.91MN/A-3.9340OLMAOlema Pharmaceuticals1.8195 of 5 stars$5.59-3.0%$24.00+329.3%-52.3%$383.64MN/A-2.8270RCKTRocket Pharmaceuticals4.8551 of 5 stars$3.54-2.7%$16.73+372.7%-82.7%$381.98MN/A-1.41240ZYBTZhengye BiotechnologyN/A$8.00+14.6%N/AN/A$377.36M$25.53M0.00278News Coverage Related Companies and Tools Related Companies Corvus Pharmaceuticals Competitors Kamada Competitors Aura Biosciences Competitors I-Mab Competitors Y-mAbs Therapeutics Competitors Aquestive Therapeutics Competitors Vigil Neuroscience Competitors Olema Pharmaceuticals Competitors Rocket Pharmaceuticals Competitors Zhengye Biotechnology Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:SAVA) was last updated on 8/27/2025 by MarketBeat.com Staff From Our PartnersMusk’s Project Colossus could mint millionairesI predict this single breakthrough could make Elon the world’s first trillionaire — and mint more new milliona...Brownstone Research | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredBONUS GUIDE - Ben Stein Prepares For the Next Financial CrisisWith inflation high, debt soaring, and global tensions rising, a financial storm may be brewing. Economist ...Goldco Precious Metals | SponsoredThis is my Christian duty“This land I will give to you…” — a 4,000-year-old line from Genesis may hold the key to unlocking a $150 tril...Paradigm Press | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredAlex’s “Next Magnificent Seven” stocksThe original “Magnificent Seven” turned $7K into $1.18 million. Now, Alex Green has identified AI’s Next Ma...The Oxford Club | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredOut of 18,347 Cryptocurrencies... This is the ONLY OneThe Single Most Undervalued DeFi Protocol You've Never Heard Of If there's one cryptocurrency you should b...Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Cassava Sciences, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Cassava Sciences With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access